Visionary Holdings Navigates a New Era of Precision Medicine, Achieving Major Breakthroughs in Targeted Therapy
Visionary Holdings (NASDAQ: GV) is advancing in the precision medicine field, particularly in targeted therapy development. The company has made strategic investments in developing third-generation EGFR inhibitors for non-small cell lung cancer and partnered with gene sequencing companies for liquid biopsy technologies.
The company is leveraging AI-assisted drug development and has established collaborations with global biotech leaders to develop next-generation anticancer drugs targeting specific gene mutations like HER2, BRAF, and KRAS. Their clinical trial network spans North America, Europe, and Asia. They've also developed rapid at-home testing technologies for cervical and colorectal cancers.
According to McKinsey Global Institute, the global biopharmaceutical market is projected to exceed $1.5 trillion by 2030, with precision medicine expected to grow at a CAGR of over 10%.
Visionary Holdings (NASDAQ: GV) sta avanzando nel campo della medicina di precisione, in particolare nello sviluppo di terapie mirate. L'azienda ha effettuato investimenti strategici nello sviluppo di inibitori EGFR di terza generazione per il cancro polmonare non a piccole cellule e ha collaborato con aziende di sequenziamento genetico per tecnologie di biopsia liquida.
L'azienda sta sfruttando lo sviluppo di farmaci assistito dall'IA e ha stabilito collaborazioni con leader globali nel settore biotech per sviluppare farmaci antitumorali di nuova generazione mirati a specifiche mutazioni geniche come HER2, BRAF e KRAS. La loro rete di sperimentazione clinica si estende in Nord America, Europa e Asia. Hanno anche sviluppato tecnologie di test rapidi da casa per il cancro cervicale e del colon-retto.
Secondo il McKinsey Global Institute, si prevede che il mercato biopharmaceutico globale supererà 1,5 trilioni di dollari entro il 2030, con la medicina di precisione che dovrebbe crescere a un CAGR di oltre il 10%.
Visionary Holdings (NASDAQ: GV) está avanzando en el campo de la medicina de precisión, particularmente en el desarrollo de terapias dirigidas. La empresa ha realizado inversiones estratégicas en el desarrollo de inhibidores EGFR de tercera generación para el cáncer de pulmón no microcítico y se ha asociado con empresas de secuenciación genética para tecnologías de biopsia líquida.
La compañía está aprovechando el desarrollo de fármacos asistido por IA y ha establecido colaboraciones con líderes biotecnológicos globales para desarrollar medicamentos anticancerígenos de próxima generación dirigidos a mutaciones genéticas específicas como HER2, BRAF y KRAS. Su red de ensayos clínicos abarca América del Norte, Europa y Asia. También han desarrollado tecnologías de pruebas rápidas en casa para el cáncer cervical y colorrectal.
Según el McKinsey Global Institute, se proyecta que el mercado biofarmacéutico global superará los 1.5 billones de dólares para 2030, con la medicina de precisión que se espera que crezca a una CAGR de más del 10%.
비전너리 홀딩스 (NASDAQ: GV)는 정밀 의학 분야에서 특히 표적 치료 개발을 통해 발전하고 있습니다. 이 회사는 비소세포 폐암을 위한 3세대 EGFR 억제제 개발에 전략적 투자를 했으며, 액체 생검 기술을 위해 유전자 시퀀싱 회사와 협력했습니다.
회사는 AI 지원 약물 개발을 활용하고 있으며, 특정 유전자 변이를 타겟으로 하는 차세대 항암제를 개발하기 위해 글로벌 생명공학 리더들과 협력 관계를 구축했습니다. 그들의 임상 시험 네트워크는 북미, 유럽 및 아시아에 걸쳐 있습니다. 또한 자궁경부암 및 대장암을 위한 빠른 자가 테스트 기술을 개발했습니다.
맥킨지 글로벌 연구소에 따르면, 글로벌 생물 제약 시장은 2030년까지 1.5조 달러를 초과할 것으로 예상되며, 정밀 의학은 10% 이상의 CAGR로 성장할 것으로 보입니다.
Visionary Holdings (NASDAQ: GV) progresse dans le domaine de la médecine de précision, en particulier dans le développement de thérapies ciblées. L'entreprise a réalisé des investissements stratégiques dans le développement d'inhibiteurs EGFR de troisième génération pour le cancer du poumon non à petites cellules et s'est associée à des entreprises de séquençage génétique pour des technologies de biopsie liquide.
L'entreprise exploite le développement de médicaments assisté par IA et a établi des collaborations avec des leaders mondiaux de la biotechnologie pour développer des médicaments anticancéreux de nouvelle génération ciblant des mutations géniques spécifiques telles que HER2, BRAF et KRAS. Leur réseau d'essais cliniques s'étend sur l'Amérique du Nord, l'Europe et l'Asie. Ils ont également développé des technologies de tests rapides à domicile pour les cancers du col de l'utérus et colorectal.
Selon le McKinsey Global Institute, le marché biopharmaceutique mondial devrait dépasser 1,5 trillion de dollars d'ici 2030, la médecine de précision devant connaître une croissance d'un TCAC de plus de 10%.
Visionary Holdings (NASDAQ: GV) macht Fortschritte im Bereich der Präzisionsmedizin, insbesondere in der Entwicklung gezielter Therapien. Das Unternehmen hat strategische Investitionen in die Entwicklung von EGFR-Inhibitoren der dritten Generation für nicht-kleinzelliges Lungenkarzinom getätigt und eine Partnerschaft mit Unternehmen für Gen-Sequenzierung zur Entwicklung von Technologien für flüssige Biopsien geschlossen.
Das Unternehmen nutzt KI-unterstützte Arzneimittelentwicklung und hat Kooperationen mit globalen Biotech-Führern etabliert, um nächste Generation von Krebsmedikamenten zu entwickeln, die auf spezifische Genmutationen wie HER2, BRAF und KRAS abzielen. Ihr Netzwerk für klinische Studien erstreckt sich über Nordamerika, Europa und Asien. Sie haben auch Technologien für schnelle Heimtests auf Gebärmutterhals- und Dickdarmkrebs entwickelt.
Laut dem McKinsey Global Institute wird erwartet, dass der globale biopharmazeutische Markt bis 2030 über 1,5 Billionen Dollar hinauswachsen wird, wobei die Präzisionsmedizin voraussichtlich mit einer CAGR von über 10% wachsen wird.
- Strategic investments in third-generation EGFR inhibitors development
- Global clinical trial network across three continents
- Successful development of at-home cancer testing technologies
- Partnerships with leading biotech firms and AI pharmaceutical companies
- Operating in a market projected to exceed $1.5T by 2030 with 10% CAGR
- None.
Targeted therapy, an innovative treatment based on molecular biology, precisely targets diseased cells while sparing healthy ones, significantly improving treatment efficacy and reducing the side effects associated with traditional radiotherapy and chemotherapy. Drugs like Erlotinib for EGFR-mutated non-small cell lung cancer and Herceptin for HER2-positive breast cancer have markedly improved patient survival rates. With the progress of precision medicine, targeted therapy is not only excelling in cancer treatment but is also expanding into areas such as neurodegenerative diseases and autoimmune disorders. According to McKinsey Global Institute, the global biopharmaceutical market is projected to exceed
Visionary Holdings has keenly recognized the immense potential of the biopharmaceutical field and has actively invested in cutting-edge areas such as tumor-targeted therapy, gene sequencing, AI-assisted drug development, and liquid biopsy. The company is focused on advancing next-generation immunotherapies, gene editing, and precision oncology, enhancing biomarker detection and liquid biopsy technologies, and leveraging AI to accelerate drug development. It has also successfully developed rapid at-home testing technologies for cervical and colorectal cancers, increasing cancer screening coverage and providing significant convenience for early diagnosis.
In practical terms, Visionary Holdings has driven substantial breakthroughs in targeted therapy through a series of strategic investments and collaborations. The company has made strategic investments in leading biotech firms to co-develop third-generation EGFR inhibitors aimed at overcoming drug resistance in non-small cell lung cancer patients. This drug is currently in global clinical trials and has garnered widespread attention. Additionally, Visionary Holdings has partnered with top gene sequencing companies to develop liquid biopsy technologies, enabling real-time monitoring of cancer progression through non-invasive blood tests, making treatments more precise and efficient.
Furthermore, Visionary Holdings has collaborated with numerous global biotech leaders, AI pharmaceutical giants, and medical research institutions to pioneer innovative projects. In targeted drug development, the company is focusing on specific gene mutations such as HER2, BRAF, and KRAS to develop next-generation anticancer drugs. By utilizing AI drug discovery technologies, deep learning algorithms are employed to analyze protein structures, significantly speeding up drug screening and optimization. Its global clinical trial network spans
Looking ahead, the combination of targeted therapy and immunotherapy will become a trend, and AI will be deeply integrated into precision medicine, substantially shortening drug development cycles and reducing costs. The application scope of targeted therapy will continue to expand, offering hope to patients with a wider range of diseases. Visionary Holdings will continue to leverage its cutting-edge technology, strategic vision, and global collaboration network to deepen its commitment to targeted therapy and precision medicine. The company is dedicated to developing next-generation targeted drugs, improving global patient access to advanced treatments, leading the new era of precision medicine, and writing a new chapter in the pursuit of human health.
For more information, please contact:
Visionary Holdings Inc.
Investor Relations Department
Email: ir@farvision.ca
View original content:https://www.prnewswire.com/news-releases/visionary-holdings-navigates-a-new-era-of-precision-medicine-achieving-major-breakthroughs-in-targeted-therapy-302382425.html
SOURCE Visionary Holdings Inc.
FAQ
What major developments has GV achieved in targeted therapy for cancer treatment?
How is GV implementing AI in its drug development process?
What new cancer testing technologies has GV developed in 2025?
Which specific gene mutations is GV targeting in its drug development?
What is the market growth projection for GV's precision medicine sector?
